InsidersTradesSigma
Track the Meridian Bioscience INC stock price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Technology sector, Meridian Bioscience INC has logged 54 insider filings. Market capitalisation: €118.3m. The latest transaction was filed on 31 January 2023 (Disposition). Among the most active insiders: WELTZIEN LOURDES. Every trade is free.
54
Insider Decl.
n/a
Thresholds
€89,509
1 ops.
Buy Volume
n/a
8 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Meridian Bioscience INC Strong Buy (bullish), based on 1 analysts. Average price target: US$10.00.
32Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 January 2023
Declarations54 total
16,424 sharesCommon StockSEC:0001567619-23-001536:0
17,290 sharesCommon StockSEC:0001567619-23-001533:0
7,945 sharesCommon StockSEC:0001567619-23-001528:0
28,224 sharesCommon StockSEC:0001567619-23-001531:0
21,724 sharesCommon StockSEC:0001567619-23-001534:0
15,408 sharesCommon StockSEC:0001567619-23-001532:0
2,648 sharesCommon StockSEC:0001567619-23-001526:0
47,060 sharesCommon StockSEC:0001567619-23-001530:0
27,449 sharesCommon StockSEC:0001567619-23-001535:0
7,945 sharesCommon StockSEC:0001567619-23-001527:0
7,945 sharesCommon StockSEC:0001567619-23-001529:0
10,274 sharesCommon StockSEC:0001567619-23-001537:0
5,000 sharesCommon StockSEC:0001567619-23-001531:1
8,500 shares@ US$20.38100.0% of flowCommon StockSEC:0001127602-23-001129:0
374 shares@ US$31.7112.2% of flowCommon StockSEC:0001127602-22-027013:0
3,666 shares@ US$31.8349.4% of flowCommon StockSEC:0001127602-22-025893:0
4,382 shares@ US$31.8328.4% of flowCommon StockSEC:0001127602-22-025892:0
1,845 shares@ US$31.8361.3% of flowCommon StockSEC:0001127602-22-025894:0
397 shares@ US$32.0114.0% of flowCommon StockSEC:0001127602-22-025090:0
4,271 shares@ US$32.016.4% of flowCommon StockSEC:0001127602-22-025087:0
566 shares@ US$32.013.9% of flowCommon StockSEC:0001127602-22-025089:0
788 shares@ US$32.0111.3% of flowCommon StockSEC:0001127602-22-025088:0
40,269 shares@ US$31.5359.4% of flowCommon StockSEC:0001127602-22-023690:0
360 shares@ US$32.1412.5% of flowCommon StockSEC:0001127602-22-023693:0
357 shares@ US$32.145.0% of flowCommon StockSEC:0001127602-22-023692:0
25 of 54 declarations
关于 Meridian Bioscience INC
Meridian Bioscience Inc.（股票代码：VIVO）是一家总部位于美国的诊断和生命科学公司，在被收购退市之前，历史上与纳斯达克市场相关联。对于投资者而言，Meridian 最好被理解为一家专业的体外诊断和关键原材料供应商，而非一家广泛的制药公司。该公司总部位于美国俄亥俄州辛辛那提，其特许经营权围绕快速、准确且操作简单的诊断解决方案而建立。（[sec.gov](https://www.sec.gov/Archives/edgar/data/794172/000119312522290521/d384542d10k.htm?utm_source=openai)） Meridian 的运营模式长期以来围绕两个互补的业务部门组织：诊断和生命科学。诊断部门专注于临床测试系统和试剂盒，特别是针对胃肠道和呼吸道传染病以及高血铅水平。生命科学部门则为诊断制造商和研究客户提供上游构建模块，包括抗原、抗体、免疫测定阻断剂、PCR 预混液、核苷酸和生物研究试剂。这种双重结构使公司既能接触到终端市场测试需求，也能接触到诊断行业的制造供应链。（[sec.gov](https://www.sec.gov/Archives/edgar/data/794172/000119312522290521/d384542d10k.htm?utm_source=openai)） 从竞争角度来看，Meridian 在一个由规模更大、资本更雄厚的同行主导的市场中占据着一个专注的利基市场。其战略集中在快速诊断可以显著改善患者预后、现有检测方案服务不足或样本处理限制使产品性能尤为重要的疾病领域。这种定位在即时检测和专业检测中具有重要意义，但也意味着 Meridian 必须通过产品差异化、质量和渠道覆盖来持续捍卫市场份额。（[sec.gov](https://www.sec.gov/Archives/edgar/data/794172/000119312521337663/d228317d10k.htm?utm_source=openai)） 从地理上看，Meridian 保持了国际业务足迹。公司公开资料显示，其客户遍布 70 多个国家，并在美国、英国、法国、德国、中国和澳大利亚设有直销网络。该公司还强调了在北京设立办事处以更好地服务中国客户。对于投资者而言，这很重要，因为它减少了对单一地理区域的依赖，同时仍使业务面临多个医疗系统中的监管、报销和竞争动态。（[meridianbioscience.com](https://www.meridianbioscience.com/press-release/meridian-bioscience-launches-lyo-ready-saliva-specific-isothermal-amplification-master-mixes-for-direct-detection-of-dna-rna-in-point-of-care-diagnostic-assays/?utm_source=openai)） 公司近期沟通强调了面向体外诊断制造商的可持续发展创新、新的生命科学原材料产品以及公司在公共卫生相关铅检测中的作用。2024 年，Meridian 描述了一套全面的、环保且经济高效的 IVD 开发商解决方案，而 2025 年，它公布了与铅检测创新和 CDC Lead Detect Prize 相关的认可。这些更新强化了 Meridian 的信息，即它不仅是试剂盒供应商，也是诊断试剂开发商的关键供应合作伙伴。（[meridianbioscience.com](https://www.meridianbioscience.com/press-release/meridian-bioscience-leads-the-way-with-innovative-sustainable-solutions-for-in-vitro-diagnostic-manufacturers/?country=US&utm_source=openai)） 因此，对于讲法语的投资者而言，Meridian 应被视为一个利基诊断平台，具有经常性消耗品和试剂敞口、国际分销以及专注于专业临床和生命科学应用。在 SEC Form 4 内部交易分析的背景下，该公司的投资案例通常取决于专业诊断的执行、产品创新以及客户关系的持久性，而非仅仅规模。（[sec.gov](https://www.sec.gov/Archives/edgar/data/794172/000119312522290521/d384542d10k.htm?utm_source=openai)）
